Tcr2 Therapeutics

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2023

Earnings data Q2 2023

CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR) (TCR² or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced fourth quarter and full-year 2022 financial results and provided a corporate update.

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Adaptimmune Therapeutics

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP). Under the terms of the proposed transaction, shareholders of TCR² will receive 1.5117 ADS of Adaptimmune for each share of TCR² that they own.

TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

Jasper Therapeutics

Precigen

Quotient Technology

thredUP

Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts, Targets Up To 952%

NEW YORK , March 6, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating TCR² Therapeutics Inc. (NASDAQ: TCRR), relating to its proposed sale to Adaptimmune Therapeutics plc. Under the terms of the agreement, TCRR shareholders are expected to receive 1.5117 shares of Adaptimmune per share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of TCR² Therapeutics Inc. - TCRR

TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDAQ: ADAP ). Meanwhile, Adaptimmune is falling more than 15%.

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

MILWAUKEE , March 6, 2023 /PRNewswire/ -- Ademi LLP is investigating TCR² (NASDAQ: TCRR) for possible breaches of fiduciary duty and other violations of law in its transaction with Adaptimmune.  Click here to learn how to join the action https://www.ademilaw.com/case/tcr2-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of TCR² Therapeutics Inc. (NASDAQ: TCRR) to Adaptimmune Therapeutics plc for 1.5117 Adaptimmune ADS for each TCR² share is fair to TCR² shareholders. Following the closing of the transaction, TCR² stockholders will own approximately 25% of the combined company.

TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m.

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gavo-cel for the treatment of patients with mesothelin tumors; Focus shift more towards targeting ovarian cancer patients with expected data 2nd half of 2023.

TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path

CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.

TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023

Fate Therapeutics

Century Therapeutics

Layoffs have been making headlines so far in 2023, even though we're just a few days into the new year. That's true even for gene-editing stocks.

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC

CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 9,600 shares of TCR2's common stock to 3 new non-executive employees. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4).

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced its pipeline priorities for 2023 as it concentrates resources on completing the ovarian cancer cohort in the Phase 2 clinical trial of gavo-cel and accelerating the development of its second-generation enhanced TRuC T-cell therapy programs, TC-510 and TC-520.

TCR² Therapeutics Announces Pipeline Priorities for 2023

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) --  TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 24,400 shares of TCR2's common stock to 3 new non-executive employees. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4).

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.

TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference

TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the poster presentation of new preclinical data at the Society for Immunotherapy of Cancer (SITC) Conference 37th Annual Meeting, taking place November 8-12, 2022. The poster entitled “The Functional Activity of gavo-cel TRuC-T Cells is Not Impaired by Soluble Mesothelin” highlights preclinical data evaluating the impact of soluble mesothelin at high, supraphysiological levels on the functional activity of the Company's proprietary autologous and allogeneic mesothelin-directed T Cell Receptor Fusion Construct (TRuC®) T cells.

TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer

- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET

gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T.

TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.

TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 7,600 shares of TCR2's common stock to 2 new non-executive employees. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4).

TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TCR² Therapeutics is a company developing two lead oncology drug candidates targeting mesothelin, a protein expressed on different tumors. Its lead candidate gavo-cel, or TC-210, has presented strong data so far in different solid tumors, including tumor regression in 94% of evaluable patients and a manageable safety profile.

TCR² Therapeutics: Betting On A Solid Reversal

- gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 - Expansion of manufacturing capacity and commencement of gavo-cel clinical trial material production at ElevateBio BaseCamp

News for Tcr2 Therapeutics Stock (TCRR)